142 related articles for article (PubMed ID: 2590312)
1. Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma.
Paar WD; Schuhler H; Fimmers R; Dengler HJ
Eur J Clin Pharmacol; 1989; 36(6):555-60. PubMed ID: 2590312
[TBL] [Abstract][Full Text] [Related]
2. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
3. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
Madsen H; Nielsen KK; Brøsen K
Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
[TBL] [Abstract][Full Text] [Related]
4. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
Nielsen KK; Brøsen K; Hansen MG; Gram LF
Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
Brøsen K; Gram LF
Eur J Clin Pharmacol; 1989; 36(6):537-47. PubMed ID: 2570698
[TBL] [Abstract][Full Text] [Related]
6. A sensitive capillary GC assay for the determination of sparteine oxidation products in microsomal fractions of human liver.
Osikowska-Evers BA; Eichelbaum M
Life Sci; 1986 May; 38(19):1775-82. PubMed ID: 3702606
[TBL] [Abstract][Full Text] [Related]
7. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.
Nielsen F; Rosholm JU; Brøsen K
Eur J Clin Pharmacol; 1995; 48(6):501-4. PubMed ID: 8582470
[TBL] [Abstract][Full Text] [Related]
8. Oxidative phenotype polymorphism (P450 2D6) and metabolism of toluene.
Pelclová D; Mráz J; Patzelová V; Pícková J; Pospísil J; Vodicková L; Hornychová M; Vejlupková J
Int J Clin Pharmacol Ther; 1996 Jan; 34(1):38-42. PubMed ID: 8688995
[TBL] [Abstract][Full Text] [Related]
9. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.
Bock KW; Schrenk D; Forster A; Griese EU; Mörike K; Brockmeier D; Eichelbaum M
Pharmacogenetics; 1994 Aug; 4(4):209-18. PubMed ID: 7987405
[TBL] [Abstract][Full Text] [Related]
10. Sparteine oxidation polymorphism in Greenlanders living in Denmark.
Brøsen K
Br J Clin Pharmacol; 1986 Oct; 22(4):415-9. PubMed ID: 3768256
[TBL] [Abstract][Full Text] [Related]
11. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
13. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.
Pedersen RS; Damkier P; Brosen K
Clin Pharmacol Ther; 2005 Jun; 77(6):458-67. PubMed ID: 15961977
[TBL] [Abstract][Full Text] [Related]
14. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
Ebner T; Eichelbaum M
Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
[TBL] [Abstract][Full Text] [Related]
15. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
Drøhse A; Bathum L; Brøsen K; Gram LF
Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
[TBL] [Abstract][Full Text] [Related]
16. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.
Gram LF; Brøsen K
Br J Clin Pharmacol; 1993 Jun; 35(6):649-52. PubMed ID: 8329293
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation.
Zekorn C; Achtert G; Hausleiter HJ; Moon CH; Eichelbaum M
Klin Wochenschr; 1985 Nov; 63(22):1180-6. PubMed ID: 4079282
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population.
Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I
Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247
[TBL] [Abstract][Full Text] [Related]
19. Sparteine oxidation polymorphism: a family study.
Brøsen K; Otton SV; Gram LF
Br J Clin Pharmacol; 1986 Jun; 21(6):661-7. PubMed ID: 3741716
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.
Lennard MS; Iyun AO; Jackson PR; Tucker GT; Woods HF
Pharmacogenetics; 1992 Apr; 2(2):89-92. PubMed ID: 1302046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
